GoKawiilChina leads global trials of in vivo CAR-T cell therapies, analysis finds
A Boston Consulting Group analysis found that of 140 in vivo CAR-T-cell drugs currently being tested in animals or humans worldwide, 82% originate from Chinese developers, even though most early preclinical research came from the US and Germany. Researchers note China has moved unusually fast in pushing these therapies into clinical trials, with early results from at least one human trial for an autoimmune condition described as promising.
GoKawiil's interpretation of the reporting above, not reported fact.
In vivo CAR-T therapies edit immune cells directly inside the body, avoiding the costly lab-based collection and engineering steps required by existing ex vivo treatments, which could make cancer and autoimmune care cheaper and more accessible if trials succeed. Researchers such as Emily Blyth suggest China's rapid clinical progress reflects sustained government backing and fast-track regulatory pathways, and note growing international interest in collaborating with Chinese groups on these therapies.
- 82% of the 140 in vivo CAR-T drugs in global trials are being developed in China.
- Foundational preclinical research largely came from the US and Germany, but China has moved fastest into clinical testing.
- Early human trial results for autoimmune disease applications are reported as promising.
Source: nature.com — Fieldhouse, 2026-09-28
Published there as: “China now leads the world in trials for next-gen CAR-T therapies”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.